- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
ADVERTISEMENT
ADVERTISEMENT
Brand Name :
Xtandi
Synonyms :
Class :
Antineoplastic agents & Antiandrogens
No drug interaction found for enzalutamide and .
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 Inducers
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of abemaciclib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of abiraterone acetate
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of abrocitinib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of acalabrutinib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alfacalcidol
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alfentanil
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alpelisib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alprazolam
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of amiodarone
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of amlodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of apixaban
CYP3A strong enhancers of the small intestine may reduce the bioavailability of apremilast
CYP3A strong enhancers of the small intestine may reduce the bioavailability of aprepitant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of aripiprazole
CYP3A enhancers may decrease plasma concentrations of the active metabolite(s) of aripiprazole lauroxil
CYP3A enhancers reduces plasma concentrations of the active metabolite(s) of artemether
CYP3A strong enhancers of the small intestine may reduce the bioavailability of asunaprevir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atazanavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atogepant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atorvastatin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avacopan
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avanafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avapritinib
enzalutamide may reduce the therapeutic efficacy of avatrombopag
CYP3A strong enhancers of the small intestine may reduce the bioavailability of axitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of barnidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bedaquiline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of belumosudil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of benidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of benperidol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of benzhydrocodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of betamethasone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bictegravir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bisoprolol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of blonanserin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bortezomib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bosutinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brentuximab vedotin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brexpiprazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brigatinib
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of brivaracetam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bromocriptine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bromperidol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of buprenorphine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of buspirone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of butorphanol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cabazitaxel
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cabozantinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of calcifediol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of calcitriol (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cannabidiol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cannabis
CYP3A strong enhancers of the small intestine may reduce the bioavailability of capmatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cariprazine
CYP2C19 enhancers may minimize the therapeutic activity of carisoprodol
CYP2C9 enhancers may decrease the the bioavailability of celecoxib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of chlorpropamide enzal
antiandrogens may diminish the therapeutic effect of choline c 11
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cilnidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of citalopram
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clarithromycin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clindamycin (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clonazepam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clozapine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cobicistat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cobimetinib
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of codeine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of copanlisib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of crizotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cyclosporine (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cyproterone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of daclatasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dapsone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of daridorexant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of darunavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dasabuvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dasatinib
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of deflazacort
CYP3A strong enhancers of the small intestine may reduce the bioavailability of delamanid
CYP3A strong enhancers of the small intestine may reduce the bioavailability of delavirdine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dexamethasone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of diazepam
CYP2C9 enhancers may decrease the the bioavailability of diclofenac (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of diltiazem
CYP3A strong enhancers of the small intestine may reduce the bioavailability of disopyramide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of domperidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of doravirine
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of doxercalciferol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of doxorubicin (conventional)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dronabinol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dronedarone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of duvelisib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dydrogesterone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ebastine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of efavirenz
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elagolix
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elbasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elexacaftor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eliglustat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elvitegravir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of encorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of enfortumab vedotin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of entrectinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eplerenone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eravacycline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of erdafitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of erlotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of escitalopram
CYP3A strong enhancers of the small intestine may reduce the bioavailability of estazolam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eszopiclone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ethosuximide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etizolam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etoposide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etoposide phosphate
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etoricoxib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etravirine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of everolimus
CYP3A strong enhancers of the small intestine may reduce the bioavailability of evogliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of exemestane
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fedratinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of felbamate
CYP3A strong enhancers of the small intestine may reduce the bioavailability of felodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fenfluramine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fentanyl
CYP3A enhancers may enhance plasma concentrations of the active metabolite(s) of fexinidazoleenzal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of finerenone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of flibanserin
CYP2C9 enhancers may decrease the the bioavailability of fluvastatin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fosaprepitant
phenytoin: enzalutamide may decrease the therapeutic efficacy of fosphenytoin-phenytoin
CYP3A enhancers (strong) may reduce the plasma concentrations of the active metabolite(s) of fostamatinib
CYP3A enhancers (strong) may reduce the plasma concentrations of the active metabolite(s) of fostemsavir
antiandrogens may decrease the therapeutic effect of gallium ga 68 psma-11
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ganaxolone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of gefitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of gemigliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of gilteritinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of glasdegib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of glecaprevir and pibrentasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of guanfacine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of haloperidol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of hormonal contraceptives
CYP3A strong enhancers of the small intestine may reduce the bioavailability of hydrocodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of hydrocortisone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ibrexafungerp i
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ibrutinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of idelalisib
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of ifosfamide enzal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of imatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of indinavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of infigratinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of irinotecan products
CYP3A strong enhancers may decrease the the bioavailability of isavuconazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of isradipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of istradefylline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of itraconazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivabradine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivacaftor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivosidenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ixabepilone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ixazomib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ketamine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ketoconazole (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lacidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lapatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of larotrectinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lefamulin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lefamulin (intravenous)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lemborexant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lercanidipine
CYP2C9 enhancers may decrease the the bioavailability of lesinurad
CYP3A strong enhancers of the small intestine may reduce the bioavailability of leuprolide and norethindrone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of levamlodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of levoketoconazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of levomethadone
CYP3A enhancers (strong) may diminish the therapeutic effect of levonorgestrel (iud) CYP3A strong enhancers of the small intestine may reduce the bioavailability of levonorgestrel (iud)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lidocaine (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of linagliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lonafarnib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lopinavir
CYP3A enhancers (strong) may enhance the hepatotoxic effect of lorlatinib CYP3A strong enhancers of the small intestine may reduce the bioavailability of lorlatinib
CYP2C9 enhancers may decrease the the bioavailability of lornoxicam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lumacaftor and ivacaftor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lumateperone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lurasidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lurbinectedin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of macimorelin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of macitentan
CYP3A strong enhancers of the small intestine may reduce the bioavailability of manidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of maraviroc
CYP3A strong enhancers of the small intestine may reduce the bioavailability of maribavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mavacamten
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mefloquine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of meperidine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methadone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methylergonovine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methylprednisolone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mianserin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of midazolam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of midostaurin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mifepristone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirabegron
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirodenafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirtazapine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mitapivat
mobocertinib: CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of mobocertinib and may reduce the bioavailability of mobocertinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of naldemedine enzal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of naloxegol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nateglinide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nelfinavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of neratinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of netupitant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nevirapine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nicardipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nifedipine management: avoid coadministration of nifedipine with strong CYP3A enhancers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nilotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nilvadipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nimodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nintedanib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nirmatrelvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nisoldipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nitrendipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of olaparib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of oliceridine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of olmutinib
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of omeprazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ondansetron
CYP3A strong enhancers of the small intestine may reduce the bioavailability of osilodrostat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of osimertinib
enzalutamide may reduce the therapeutic efficacy of ospemifene
CYP3A strong enhancers of the small intestine may reduce the bioavailability of oxcarbazepine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of oxycodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of paclitaxel (conventional)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of paclitaxel (protein bound)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pacritinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of palbociclib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of panobinostat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pazopanib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pemigatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of perampanel
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pexidartinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pimavanserin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of piperaquine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pitolisant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of polatuzumab vedotin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ponatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pralsetinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of praziquantel
CYP3A strong enhancers of the small intestine may reduce the bioavailability of prednisolone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of prednisone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pretomanid
CYP3A strong enhancers of the small intestine may reduce the bioavailability of propafenone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quetiapine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quinidine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quinine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of radotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ramelteon
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ranolazine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of reboxetine
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of regorafenib and it may reduce the bioavailability of regorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of remdesivir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of repaglinide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ribociclib
may reduce the therapeutic efficacy of enzalutamide
may reduce the therapeutic efficacy of enzalutamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rilpivirine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rimegepant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of riociguat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ripretinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of risperidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ritonavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rivaroxaban
CYP3A strong enhancers of the small intestine may reduce the bioavailability of roflumilast
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rolapitant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of romidepsin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ruxolitinib (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of samidorphan
CYP3A strong enhancers of the small intestine may reduce the bioavailability of saquinavir management: consider alternatives to strong CYP3A enhancers in patients treated with saquinavir if combined, monitor closely for signs of decreased saquinavir concentrations and effects
CYP3A strong enhancers of the small intestine may reduce the bioavailability of saxagliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of selpercatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of selumetinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sertindole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sertraline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sildenafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of simeprevir
enzalutamide may reduce the therapeutic efficacy of siponimod
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sirolimus (conventional)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sirolimus (protein bound)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of solifenacin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sonidegib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sotorasib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of stiripentol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sufentanil
CYP2C9 enhancers may decrease the the bioavailability of sulfonylureas
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sunitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of suvorexant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tacrolimus (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tadalafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tamoxifen
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tasimelteon
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tazemetostat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of telithromycin
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of temsirolimus
CYP3A strong enhancers of the small intestine may reduce the bioavailability of teniposide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tepotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tetrahydrocannabinol tetrahydrocannabinol and cannabidiol: CYP3A strong enhancers of the small intestine may reduce the bioavailability of tetrahydrocannabinol and cannabidiol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tezacaftor and ivacaftor
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of thiotepa and reduce the the bioavailability of thiotepa
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tiagabine
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of ticagrelor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tipranavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tivozanib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tofacitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tolvaptan
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of toremifene
CYP2C9 enhancers may decrease the the bioavailability of torsemide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of trabectedin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tramadol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of trazodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of triamcinolone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of triazolam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tropisetron
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tucatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ubrogepant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of udenafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ulipristal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of upadacitinib
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of vandetanib and reduce the the bioavailability
CYP3A strong enhancers of the small intestine may reduce the bioavailability of velpatasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vemurafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of venetoclax
CYP3A strong enhancers of the small intestine may reduce the bioavailability of verapamil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vilazodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vincristine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vincristine (liposomal)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vinflunine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vinorelbine
vitamin k antagonists (eg warfarin)
enzalutamide may reduce the therapeutic efficacy of vitamin k antagonists
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voclosporin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vonoprazan
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vorapaxar
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voriconazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vortioxetine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voxelotor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voxilaprevir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zaleplon
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zanubrutinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ziprasidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zolpidem
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zonisamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zopiclone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zuclopenthixol
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
the effect of enzalutamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
it decreases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in a high level of serum concentration
has an antagonistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
may diminish the serum concentration
Dosage forms & Strengths
Capsule, Oral:
40 mg
Tablet, Oral:
40 mg
80 mg
Note: Patients under enzalutamide therapy should also be accompanied by a gonadotropin-releasing hormone analog concurrently
Metastatic:
160
mg
orally
once a day
Dose Adjustments
Frequency defined:
>10%:
Hypertension (14%)
Peripheral edema (15%)
Decreased appetite
Hypermagnesemia
Weight loss (12%)
Decreased white blood cells
Diarrhea
Nausea
Dizziness
Fatigue
Headache
Muscle pain
Dyspnea
Back pain
1% to 10%
Cardiac arrhythmia (3%)
Pruritis
Bone fracture
Anxiety
Cognitive dysfunction
Insomnia
Restless leg
Hematuria
Muscle rigidity
<1%
Tongue edema
Seizure
Facial edema
Frequency not defined:
Hypersensitivity reaction
Pregnancy consideration: No data available regarding pregnancy effects of enzalutamide.
Lactation: excretion of enzalutamide in breast milk is unknown.
Pregnancy category:
Patient information leaflet
Generic Name: Enzalutamide
Pronounced: enza-lu-ta-myd
Why do we use enzalutamide?
Enzalutamide is an antiandrogen class of antineoplastic drug. It is used to treat prostate cancer.
ADVERTISEMENT
Brand Name :
Xtandi
Synonyms :
Class :
Antineoplastic agents & Antiandrogens
Dosage forms & Strengths
Capsule, Oral:
40 mg
Tablet, Oral:
40 mg
80 mg
Note: Patients under enzalutamide therapy should also be accompanied by a gonadotropin-releasing hormone analog concurrently
Metastatic:
160
mg
orally
once a day
Dose Adjustments
